Anshan Hifichem Co Ltd
Anshan Hifichem Co Ltd is a Chinese specialty chemicals company that produces and sells chemical products, primarily serving industrial and manufacturing sectors.
Business. Anshan Hifichem Co Ltd (300758.SZ) is a specialty chemicals manufacturer headquartered in China. The company operates within the Basic Materials sector, specifically focusing on the production and sale of chemical products. It is primarily listed on the Shenzhen Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Anshan Hifichem Co Ltd (300758.SZ) is a specialty chemicals manufacturer headquartered in China. The company operates within the Basic Materials sector, specifically focusing on the production and sale of chemical products. It is primarily listed on the Shenzhen Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
Anshan Hifichem maintains a debt-to-equity ratio of 0.73, indicating a moderate reliance on debt financing, and a current ratio of 1.29, suggesting limited short-term liquidity cushion. Free cash flow is positive at 14.02 million CNY, but operating cash flow of 63.92 million CNY is constrained by capital expenditures of -162.18 million CNY, reflecting ongoing investment in infrastructure or production capacity.
Profitability metrics show a return on equity of 3.46% and a return on assets of 1.56%, both below the typical thresholds for high-margin specialty chemical firms. The company's net income of 61.16 million CNY is supported by a gross profit of 454.80 million CNY, but operating income of 63.59 million CNY suggests pressure from operating expenses.
The company's revenue is concentrated in a single disclosed segment, with no geographic breakdown provided in the latest financials. This lack of diversification increases exposure to regional economic shifts and regulatory changes in China.
Looking ahead, revenue is expected to grow, though the exact rate is not specified. The company's capital expenditures suggest a focus on maintaining or expanding production capabilities, which could support long-term growth but may also strain near-term cash flow.
Risk factors include a medium liquidity rating and a negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no near-term pressure from share issuance or convertible debt. However, the company's reliance on debt financing and limited operating cash flow could become more problematic if interest rates rise or credit conditions tighten.
Recent filings and transcripts are not available in the provided data, so no specific events can be cited for the most recent period. Analysts have assigned a mean recommendation of 1.00 (strong buy), with one strong-buy rating and no buy, hold, sell, or strong-sell ratings, indicating strong confidence in the company's near-term prospects.
- Anshan Hifichem operates in the low-margin end of the specialty chemicals industry, with ROE and ROA below typical benchmarks.
- The company is moderately leveraged, with a debt-to-equity ratio of 0.73 and a current ratio of 1.29.
- Free cash flow is positive but constrained by capital expenditures, suggesting ongoing investment in operations.
- Analysts are bullish, with a mean recommendation of 1.00 (strong buy), but the company's financials suggest limited upside unless margins improve.
- Revenue concentration in a single segment and geographic exposure to China increase operational and regulatory risk.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,41 |
| Revenue | —no estimate | —no estimate | 1,9B CNY |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Anshan Hifichem Co Ltd Market data — financials · 2026-05-26
- Anshan Hifichem Co Ltd Market data — analyst estimates · 2026-05-26